Skip to content

Scholar Rock SRRK Other Commercial Liabilities

Other Commercial Liabilities at other companies

Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
Arrowhead Research logo
Arrowhead ResearchARWR
Cytokinetics logo
CytokineticsCYTK
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$6.14B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Reported directly by Scholar Rock in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's other commercial liabilities?
Scholar Rock (SRRK) reported other commercial liabilities of $44.35M in Q1 2026.
How has Scholar Rock's other commercial liabilities changed year-over-year?
Scholar Rock's other commercial liabilities increased by 60.5% year-over-year, from $27.64M to $44.35M.
What is the long-term trend for Scholar Rock's other commercial liabilities?
Over 5 years (2020 to 2025), Scholar Rock's other commercial liabilities has grown at a 21.5% compound annual growth rate (CAGR), from $14.96M to $39.57M.